TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

TLDR Biotech is currently a one-person show that works full-time to put together these compilations and related content.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE GOOD
Clinical Trials

Gilead’s $4.3B CymaBay acquisition paying off, presents 2 year improvement outcomes post-Ph3
Small molecule, liver disease, primary biliary cholangitis - Read more

Not to be outdone, Ipsen releases positive Ph3 data for the same indication 
Small molecule, primary biliary cholangitis - Read more

Eli Lilly shows-off sMASHing Ph2 data
GIP/GLP-1, metabolic dysfunction-associated steatohepatitis - Read more

Vir Biotechnology’s Hepatitis Delta interim Ph2 data looks good
Monoclonal antibody, hepatitis delta - Read more

Amgen’s $27.8B buyout of Horizon Therapeutics delivers the goods with Ph3 success for IgG4-RD, rare disease
Monoclonal antibody, progressive fibroinflammatory disorder immunoglobulin G4-related disease - Read more

Equillium isn’t SALTy about their positive topline Ph2 data
Peptide, alopecia areata - Read more

Gene therapy clinical trial targeting inherited deafness sees more children treated
Gene therapy, inherited deafness - Read more [Paywall]

Proton therapy does the cancer-disappear trick with less malnutrition and feeding tube dependency, Ph3 trial
Radiation therapy, proton therapy, head & neck cancer - Read more

THE GOOD
Fundraises

Annexon common stock sale, $125M
Antibody, small molecule, neuroinflammatory diseases - Read more

SciTech $3.2M additional raise
Small molecule, lymphoma, lung cancer - Read more

Saguaro Biosciences $3M Seed raise
Reagents, cell-imaging, cell analysis - Read more

Raydiant Oximetry $7.5M Extension Series A
Medical device, childbirth - Read more

AcuityMD $45M Series B
Medical technology commercial intelligence - Read more

Eko Health $41M Series D
Medical device, AI, lung disease, heart disease - Read more

THE GOOD
Investments

SOFIE Biosciences investment from Trilantic North America private equity firm (amount undisclosed)
CDMO, radiopharmaceuticals - Read more

THE GOOD
IPOs

Telix Pharmaceuticals plans for $200M IPO
Radiopharmaceuticals, PET imaging, kidney cancer - Read more

THE GOOD
Partnerships

ArriVent BioPharma ADC discovery collab with Alphamab Biopharmaceuticals
Alphamab eligible for up to $615.5M (up-front + biobucks)
Antibody-drug conjugate, cancer - Read more

Massive Bio clinical trial matching partnership with Inocras
AI, sequencing & bioinformatics, cancer clinical trial matching - Read more

THE GOOD
Product Launches

Dexcom diabetes sensor now syncs to Apple Watch
Medical device, consumer health, diabetes - Read more

THE GOOD
Research

We might have found the genetic driver for IBD and other immune disorders
Inflammatory bowel disease, autoimmune - Read more

THE GOOD
Strategic Plans

Eli Lilly doesn’t believe it’s never lupus
Drug discovery research, lupus - Read more [Paywall]

THE BAD
Layoffs

Bristol Myers Squibb’s savings campaign in full swing with 860+ job cuts - Read more

THE BAD
Mergers & Acquisitions

Cytokinetics had a potential buyer walk away, CEO comments
Small molecule, symptomatic obstructive hypertrophic cardiomyopathy - Read more

THE UGLY
Clinical Trials

“We told you this could happen” [paraphrasing] - Rayze Bio warned investors about potential isotope shortages
Radiopharmaceuticals, gastroenteropancreatic neuroendocrine tumors - Read more [Paywall]

THE UGLY
Patient Access

USA drug shortages exacerbated by economic pressures - Read more

THE UGLY
Politics & Policy

Senate Finance Committee Chair demands US Health and Human Services Department (HHS) enforce stricter cybersecurity requirements, in wake of Change Healthcare cybersecurity incident - Read more

THE UGLY
Public Health

Finland takes no chances, may order 20k avian flu vaccines for at-risk residents
Vaccine, avian flu, bird flu - Read more

THE UGLY
Warnings Letters, Form 483

A comedy of errors; FDA hands Form 483 to Jiangsu Hengrui Pharmaceuticals - Read more*

*If you have time and want a good laugh, read “Observation 5” (page 5) in the original Form 483.

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 250+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.